Researchers discover specific probiotic strain significantly improves IBS symptoms
CINCINNATI A review by researchers at Northwestern University and University of Michigan of the utility of probiotics in the treatment of irritable bowel syndrome found that Bifidobacterium infantis 35624 was the only probiotic strain out of 13 different individual strains or preparations reviewed to significantly improve symptoms of IBS, including abdominal pain, bloating and bowel movement difficulty.
The researchers reviewed 16 random-controlled-studies, evaluating the efficacy, safety and tolerability of probiotics in the treatment of IBS. With the exception of the Bifidobacterium infantis 35624 studies, researchers found the other trials did not use an appropriate study design and did not adequately report adverse events. The article was published on the American Journal of Gastroenterology Web site in advance of appearing in the publication’s April 2009 issue.
Irritable bowel syndrome affects 1-in-5 Americans and treatment options are limited. Darren Brenner, Division of Gastroenterology and Department of Internal Medicine, at Northwestern University and lead investigator of this study, hypothesized that alterations in gut microflora may contribute to the development of IBS symptoms, and believed these symptoms could be improved by probiotics.
“Probiotics are gaining popularity for the treatment of multiple gastrointestinal disorders, including IBS,” Brenner said. “After assessment of the methodological and statistical designs of these studies, B. infantis 35624 was the only probiotic that showed repeated efficacy.”
AAFA, Alcon team up to spread allergy awareness
FORT WORTH, Texas An eye care company will work with the Asthma and Allergy Foundation of America to educate patients about treating allergy symptoms quickly and efficiently.
The AAFA and Alcon announced Friday that they will begin spreading the word about seasonal allergies and treatment through media outlets.
“There are some new concepts and new treatments for the springtime problems people are already experiencing,” University of North Texas Health Science Center clinical professor Bobby Lanier said. “Doctors have just completed their annual conference on allergy and are eager to join our friends at AAFA and communicate about these advances.”
Seasonal allergies affect 40 to 50 million people in the United States and are one of the major reasons for work and school absenteeism, according to the AAFA.
ProActive Remedies develops drug for food-allergy sufferers
FORT COLLINS, Colo. ProActive Remedies on Thursday announced the launch of its homeopathic food allergy treatment called Allertherapy.
The methodology behind Allertherapy is similar in concept to allergy shots, the company noted, in that it helps build immunity to allergens and maintains that immunity over time. The oral spray uses a low, homeopathic allergen strength of one part per million to allow for safety of use in most allergy sufferers. The food mix contains many of the most common allergy-causing foods.
Because Allertherapy contains allergens, it is important to note that those with severe allergies must only use this treatment with doctor approval and under doctor supervision, the company stated.